Velaglucerase alfa (VPRIV) is indicated as a long-term enzyme replacement therapy for patients with type 1 Gaucher disease. Gaucher disease is caused by mutations in the GBA gene, resulting in a deficiency of the enzyme beta-glucocerebrosidase. Velaglucerase alfa has the same amino acid sequence as naturally occurring glucocerebrosidase.
Excerpts from the velaglucerase alfra (VPRIV) drug label:
VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
Velaglucerase alfa is a glycoprotein...[it] has the same amino acid sequence as the naturally occurring human enzyme, glucocerebrosidase.
Gaucher disease is an autosomal recessive disorder caused by mutations in the GBA gene, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase.
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the velaglucerase alfa drug label.
*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.
Genes and/or phenotypes found in this label
- Indications & usage section, Description section, Clinical pharmacology section, other
- source: FDA Label